France: Ipsen bolstering Rare Disease portfolio with Albireo acquisition

Euronext-listed Ipsen, a Paris-based mid-sized biopharmaceutical company focused on oncology, rare disease and neuroscience has agreed to acquire Nasdaq-listed, US-based Albireo a company specialising in bile-acid modulators to treat paediatric and adult cholestatic liver diseases. The acquisition will bolster Ipsen’s Rare Disease portfolio and pipeline. Ipsen will make a tender offer to acquire all outstanding…

You must be a HMI Subscriber to view this content.

Subscribe Now »